The firm is conducting a multi-center prospective clinical study to validate its liquid biopsy ctDNA test, which it plans to launch for pharma customers this year and commercially in 2016.
Gene panel testing of cancer patients helps clinicians identify actionable mutations, according to presenters at this year's AACC meeting.
EDGC will have exclusive distribution rights in South Korea for the OncoDEEP Dx panel and other technologies, while physicians there will be able to access the OncoShare web platform.
Last month, the company presented results from a pilot study at the Worldwide Innovative Networking (WIN) Symposium in Paris.
Deck: The panels, which cover lung, colon, brain, and thyroid cancer as well as melanoma and gastrointestinal stromal tumors, target newly diagnosed patients.
So far, results from the MSK-IMPACT test have been reported for more than 4,500 patients.
The UCSF spinout was founded last year and has been selling an FFPE DNA extraction kit and three NGS cancer panels.
The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.
GATC Biotech will sell and market Molecular Health's TreatmentMap next-generation sequencing-based tumor profiling platform around the world.
Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.